Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies
- PMID: 19711424
- DOI: 10.1002/hep.23123
Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies
Abstract
We have made striking progress in our understanding of the biochemistry and cell biology that underlies liver fibrosis and cirrhosis, including the development of strategies and agents to prevent and reverse fibrosis. However, translation of this knowledge into clinical practice has been hampered by (1) the limitation of many in vitro and in vivo models to confirm mechanisms and to test antifibrotic agents, and (2) the lack of sensitive methodologies to quantify the degree of liver fibrosis and the dynamics of fibrosis progression or reversal in patients. Furthermore, whereas cirrhosis and subsequent decompensation are accepted hard clinical endpoints, fibrosis and fibrosis progression alone are merely plausible surrogates for future clinical deterioration. In this review we focus on an optimized strategy for preclinical antifibrotic drug development and highlight the current and future techniques that permit noninvasive assessment and quantification of liver fibrosis and fibrogenesis. The availability of such noninvasive methodologies will serve as the pacemaker for the clinical development and validation of potent antifibrotic agents.
Similar articles
-
Rationale and targets for antifibrotic therapies.Gastroenterol Clin Biol. 2009 Oct-Nov;33(10-11):949-57. doi: 10.1016/j.gcb.2009.07.021. Epub 2009 Sep 1. Gastroenterol Clin Biol. 2009. PMID: 19726145 Review.
-
Anti-fibrotic therapy: lost in translation?J Hepatol. 2012;56 Suppl 1:S66-74. doi: 10.1016/S0168-8278(12)60008-7. J Hepatol. 2012. PMID: 22300467 Review.
-
[Liver fibrosis: pathophysiology, diagnosis and treatment].Orv Hetil. 2005 Jan 2;146(1):3-13. Orv Hetil. 2005. PMID: 15715367 Review. Hungarian.
-
Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications.Nat Clin Pract Gastroenterol Hepatol. 2004 Dec;1(2):98-105. doi: 10.1038/ncpgasthep0055. Nat Clin Pract Gastroenterol Hepatol. 2004. PMID: 16265071 Review.
-
[Reversibility of advanced liver fibrosis--therapeutic possibility and biochemical monitoring of the disease].Przegl Epidemiol. 2005;59(2):535-40. Przegl Epidemiol. 2005. PMID: 16190564 Review. Polish.
Cited by
-
Activated hepatic stellate cells upregulate transcription of ecto-5'-nucleotidase/CD73 via specific SP1 and SMAD promoter elements.Am J Physiol Gastrointest Liver Physiol. 2012 Oct 15;303(8):G904-14. doi: 10.1152/ajpgi.00015.2012. Epub 2012 Aug 16. Am J Physiol Gastrointest Liver Physiol. 2012. PMID: 22899823 Free PMC article.
-
Efficient liver repopulation of transplanted hepatocyte prevents cirrhosis in a rat model of hereditary tyrosinemia type I.Sci Rep. 2016 Aug 11;6:31460. doi: 10.1038/srep31460. Sci Rep. 2016. PMID: 27510266 Free PMC article.
-
Kindlin-2 regulates hepatic stellate cells activation and liver fibrogenesis.Cell Death Discov. 2018 Sep 12;4:34. doi: 10.1038/s41420-018-0095-9. eCollection 2018. Cell Death Discov. 2018. PMID: 30245857 Free PMC article.
-
Role of platelet factor 4 in arteriovenous fistula maturation failure: What do we know so far?J Vasc Access. 2024 Mar;25(2):390-406. doi: 10.1177/11297298221085458. Epub 2022 Jun 24. J Vasc Access. 2024. PMID: 35751379 Free PMC article. Review.
-
Experimental liver fibrosis research: update on animal models, legal issues and translational aspects.Fibrogenesis Tissue Repair. 2013 Oct 1;6(1):19. doi: 10.1186/1755-1536-6-19. Fibrogenesis Tissue Repair. 2013. PMID: 24274743 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical